Protagenic Reconciled Depreciation vs Selling General Administrative Analysis

Stocks . USA . 
Stock . Protagenic Therapeutics
PTIX Stock  USD 0.65  0.04  6.56%   
Protagenic Therapeutics financial indicator trend analysis is much more than just breaking down Protagenic Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protagenic Therapeutics is a good investment. Please check the relationship between Protagenic Therapeutics Reconciled Depreciation and its Selling General Administrative accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagenic Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.

Reconciled Depreciation vs Selling General Administrative

Reconciled Depreciation vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protagenic Therapeutics Reconciled Depreciation account and Selling General Administrative. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Protagenic Therapeutics' Reconciled Depreciation and Selling General Administrative is -0.09. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Protagenic Therapeutics, assuming nothing else is changed. The correlation between historical values of Protagenic Therapeutics' Reconciled Depreciation and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of Protagenic Therapeutics are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Reconciled Depreciation i.e., Protagenic Therapeutics' Reconciled Depreciation and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

-0.09
Relationship DirectionNegative 
Relationship StrengthInsignificant

Reconciled Depreciation

Selling General Administrative

Most indicators from Protagenic Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protagenic Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagenic Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.Selling General Administrative is likely to drop to about 1.1 M in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year
 2021 2022 2023 2024 (projected)
Reconciled Depreciation37.030.01.6K1.7K
Interest Income33.2K185.8K303.2K318.4K

Protagenic Therapeutics fundamental ratios Correlations

Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Common Stock
Accounts Payable
Short Term Investments
Current Deferred Revenue
Other Assets
Net Tangible Assets
Total Assets
-0.340.1-0.090.65-0.18-0.33-0.030.22-0.19-0.191.0-0.240.58-0.250.68-0.07-0.110.97-0.24-0.24-0.120.93-0.2-0.270.83
Short Long Term Debt Total
-0.34-0.090.54-0.630.360.76-0.48-0.240.370.37-0.310.83-0.260.87-0.230.790.57-0.350.950.830.57-0.220.38-0.28-0.38
Other Current Liab
0.1-0.09-0.270.260.64-0.210.250.160.640.640.12-0.440.7-0.4-0.04-0.39-0.270.09-0.05-0.44-0.310.230.64-0.440.07
Total Current Liabilities
-0.090.54-0.27-0.81-0.10.38-0.980.03-0.1-0.1-0.110.66-0.290.66-0.220.651.0-0.10.560.661.0-0.14-0.09-0.14-0.15
Total Stockholder Equity
0.65-0.630.26-0.81-0.03-0.520.720.16-0.04-0.040.66-0.640.59-0.650.53-0.53-0.820.67-0.57-0.64-0.820.63-0.05-0.060.65
Property Plant And Equipment Net
-0.180.360.64-0.1-0.030.290.13-0.181.01.0-0.15-0.110.35-0.05-0.11-0.14-0.09-0.180.4-0.11-0.080.11.0-0.12-0.13
Net Debt
-0.330.76-0.210.38-0.520.29-0.31-0.790.310.32-0.310.61-0.310.65-0.090.530.42-0.370.710.610.42-0.070.320.03-0.45
Retained Earnings
-0.03-0.480.25-0.980.720.13-0.31-0.10.130.14-0.01-0.610.15-0.610.16-0.65-0.98-0.04-0.51-0.61-0.970.040.130.2-0.01
Cash
0.22-0.240.160.030.16-0.18-0.79-0.1-0.19-0.210.21-0.150.22-0.18-0.05-0.060.010.3-0.22-0.150.0-0.07-0.21-0.280.37
Non Current Assets Total
-0.190.370.64-0.1-0.041.00.310.13-0.191.0-0.16-0.10.33-0.04-0.11-0.14-0.09-0.190.4-0.1-0.070.091.0-0.11-0.16
Non Currrent Assets Other
-0.190.370.64-0.1-0.041.00.320.14-0.211.0-0.15-0.10.32-0.04-0.1-0.14-0.09-0.190.4-0.1-0.070.11.0-0.11-0.18
Cash And Short Term Investments
1.0-0.310.12-0.110.66-0.15-0.31-0.010.21-0.16-0.15-0.220.59-0.220.66-0.04-0.130.97-0.2-0.22-0.140.94-0.16-0.30.83
Common Stock Total Equity
-0.240.83-0.440.66-0.64-0.110.61-0.61-0.15-0.1-0.1-0.22-0.481.0-0.250.970.67-0.250.861.00.68-0.24-0.1-0.16-0.26
Common Stock Shares Outstanding
0.58-0.260.7-0.290.590.35-0.310.150.220.330.320.59-0.48-0.460.27-0.31-0.30.63-0.2-0.49-0.330.640.31-0.480.7
Non Current Liabilities Total
-0.250.87-0.40.66-0.65-0.050.65-0.61-0.18-0.04-0.04-0.221.0-0.46-0.250.970.67-0.260.891.00.68-0.23-0.03-0.17-0.28
Other Current Assets
0.68-0.23-0.04-0.220.53-0.11-0.090.16-0.05-0.11-0.10.66-0.250.27-0.25-0.17-0.210.64-0.26-0.25-0.220.67-0.11-0.070.41
Other Stockholder Equity
-0.070.79-0.390.65-0.53-0.140.53-0.65-0.06-0.14-0.14-0.040.97-0.310.97-0.170.66-0.060.840.970.67-0.09-0.14-0.26-0.06
Total Liab
-0.110.57-0.271.0-0.82-0.090.42-0.980.01-0.09-0.09-0.130.67-0.30.67-0.210.66-0.120.570.670.99-0.15-0.08-0.15-0.18
Total Current Assets
0.97-0.350.09-0.10.67-0.18-0.37-0.040.3-0.19-0.190.97-0.250.63-0.260.64-0.06-0.12-0.25-0.25-0.130.89-0.2-0.280.89
Short Term Debt
-0.240.95-0.050.56-0.570.40.71-0.51-0.220.40.4-0.20.86-0.20.89-0.260.840.57-0.250.860.59-0.10.41-0.25-0.24
Common Stock
-0.240.83-0.440.66-0.64-0.110.61-0.61-0.15-0.1-0.1-0.221.0-0.491.0-0.250.970.67-0.250.860.68-0.24-0.1-0.16-0.27
Accounts Payable
-0.120.57-0.311.0-0.82-0.080.42-0.970.0-0.07-0.07-0.140.68-0.330.68-0.220.670.99-0.130.590.68-0.16-0.07-0.1-0.18
Short Term Investments
0.93-0.220.23-0.140.630.1-0.070.04-0.070.090.10.94-0.240.64-0.230.67-0.09-0.150.89-0.1-0.24-0.160.09-0.240.74
Current Deferred Revenue
-0.20.380.64-0.09-0.051.00.320.13-0.211.01.0-0.16-0.10.31-0.03-0.11-0.14-0.08-0.20.41-0.1-0.070.09-0.11-0.18
Other Assets
-0.27-0.28-0.44-0.14-0.06-0.120.030.2-0.28-0.11-0.11-0.3-0.16-0.48-0.17-0.07-0.26-0.15-0.28-0.25-0.16-0.1-0.24-0.11-0.25
Net Tangible Assets
0.83-0.380.07-0.150.65-0.13-0.45-0.010.37-0.16-0.180.83-0.260.7-0.280.41-0.06-0.180.89-0.24-0.27-0.180.74-0.18-0.25
Click cells to compare fundamentals

Protagenic Therapeutics Account Relationship Matchups

High Positive Relationship

Cash And Short Term Investments
+ 1.0
Total Assets
Total Liab
+ 1.0
Total Current Liabilities
Accounts Payable
+ 1.0
Total Current Liabilities
Non Current Assets Total
+ 1.0
Property Plant And Equipment Net
Non Currrent Assets Other
+ 1.0
Property Plant And Equipment Net
Current Deferred Revenue
+ 1.0
Property Plant And Equipment Net

High Negative Relationship

Total Liab
- 0.98
Retained Earnings
Retained Earnings
- 0.98
Total Current Liabilities
Accounts Payable
- 0.97
Retained Earnings
Accounts Payable
- 0.82
Total Stockholder Equity
Total Liab
- 0.82
Total Stockholder Equity
Total Stockholder Equity
- 0.81
Total Current Liabilities

Protagenic Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets842.3K879.2K11.1M8.0M4.3M4.1M
Other Current Liab1.2M513.3K520.6K620.1K541.5K514.4K
Total Current Liabilities1.2M655.2K799.5K1.1M655.3K622.5K
Total Stockholder Equity(634.4K)(1.1M)9.9M6.9M3.7M6.1M
Property Plant And Equipment Net611.0296.00.01.8K123.3K117.2K
Net Debt(519.3K)702.7K(222.7K)129.0K(1.3M)(1.4M)
Retained Earnings(15.2M)(17.7M)(22.2M)(25.8M)(30.8M)(32.3M)
Cash798.6K671.1K541.2K215.2K1.3M2.0M
Non Current Assets Total611.0296.00.01.8K123.3K117.2K
Non Currrent Assets Other1.0K611.0296.01.8K(1.0)(0.95)
Cash And Short Term Investments798.6K671.1K10.4M8.0M4.1M4.0M
Liabilities And Stockholders Equity842.3K879.2K11.1M8.0M4.3M4.1M
Non Current Liabilities Total161.052.4K279.4K1.4M318.4K1.0M
Other Current Assets43.4K208.2K688.7K56.9K144.0K136.8K
Other Stockholder Equity14.7M16.7M32.4M33.4M34.6M42.6M
Total Liab1.5M2.0M1.1M1.1M655.3K622.5K
Total Current Assets842.0K879.2K11.1M8.0M4.2M7.2M
Accumulated Other Comprehensive Income(172.4K)(171.6K)(248.3K)(676.9K)(113.5K)(119.2K)
Accounts Payable36.2K141.9K279.0K155.5K113.8K108.1K
Net Tangible Assets(210.9K)(634.4K)(1.1M)9.9M11.4M12.0M
Net Invested Capital(355.0K)224.1K10.3M7.3M3.7M3.5M
Net Working Capital(355.3K)224.1K10.3M6.9M3.5M3.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY